CLL BTKi Therapy: FAQ Part 2
Chronic Lymphocytic Leukemia: New Horizons With BTK Inhibitors: FAQ Part 2

Released: September 16, 2020

Expiration: September 15, 2021

Danielle M. Brander
Danielle M. Brander, MD
Jeffrey P. DONOTUSESharman
Jeffrey P. DONOTUSESharman, MD
Jeff DONOTUSESharman
Jeff DONOTUSESharman, MD
Nicole Lamanna
Nicole Lamanna, MD

Activity

Progress
1
Course Completed

In this episode, Jeff P. Sharman, MD, Danielle M. Brander, MD, and Nicole Lamanna, MD, answer audience questions from a live Webinar focused on optimal use of BTK inhibitor therapy in patients with CLL, with topics including:

  • Rechallenging patients with venetoclax and BTK inhibitors
  • Mechanism by which BTK inhibitors may reduce infusion reactions
  • Risk of secondary malignancies with BTK inhibition
  • Different cytogenetic findings and adverse event risk

Content based on an online CME program supported by an educational grant from AstraZeneca.

Link to full program, including associated downloadable slidesets:
https://www.clinicaloptions.com/oncology/programs/cll-horizons